CVS GROUP PLC

National Storage Mechanism | Additional information

RNS Number : 6187K

CVS Group plc

08 December 2025

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

CVS announces that on 05 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").


Date of purchase:	05/12/2025
Aggregate number of Ordinary Shares purchased:	12,974
Lowest price paid per share (GBp):	1,200.00
Highest price paid per share (GBp):	1,214.00
Volume weighted average price paid per share (GBp):	1,211.79

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,961,055 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 70,961,055 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 779,728 Ordinary Shares in aggregate at a weighted average price of 1,215.61 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

Individual transactions:


Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue

204	1202	05/12/2025 08:02:59	1345897338243595	XLON
82	1200	05/12/2025 08:08:15	1345897338244424	XLON
459	1212	05/12/2025 08:49:22	1345897338249263	XLON
120	1208	05/12/2025 08:55:35	1345897338249854	XLON
72	1210	05/12/2025 08:59:59	1345897338250281	XLON
444	1210	05/12/2025 08:59:59	1345897338250285	XLON
82	1210	05/12/2025 09:26:59	1345897338253361	XLON
252	1214	05/12/2025 10:03:32	1345897338256451	XLON
124	1212	05/12/2025 10:24:34	1345897338257876	XLON
262	1214	05/12/2025 11:37:41	1345897338263129	XLON
196	1214	05/12/2025 12:29:44	1345897338266064	XLON
111	1214	05/12/2025 12:29:44	1345897338266067	XLON
201	1212	05/12/2025 12:49:13	1345897338267042	XLON
201	1212	05/12/2025 12:49:13	1345897338267048	XLON
43	1212	05/12/2025 12:49:13	1345897338267049	XLON
201	1212	05/12/2025 12:49:13	1345897338267050	XLON
63	1212	05/12/2025 12:49:13	1345897338267051	XLON
201	1212	05/12/2025 13:06:51	1345897338268072	XLON
72	1214	05/12/2025 13:06:51	1345897338268069	XLON
1180	1212	05/12/2025 13:06:51	1345897338268076	XLON
201	1212	05/12/2025 13:06:51	1345897338268077	XLON
263	1212	05/12/2025 13:06:51	1345897338268078	XLON
15	1212	05/12/2025 13:06:51	1345897338268079	XLON
146	1212	05/12/2025 13:25:57	1345897338268965	XLON
186	1212	05/12/2025 13:25:57	1345897338268963	XLON
6315	1212	05/12/2025 13:25:57	1345897338268969	XLON
201	1212	05/12/2025 13:25:57	1345897338268976	XLON
62	1212	05/12/2025 13:25:57	1345897338268977	XLON
201	1212	05/12/2025 13:25:57	1345897338268978	XLON
122	1212	05/12/2025 13:25:57	1345897338268980	XLON
466	1212	05/12/2025 13:25:57	1345897338268981	XLON
72	1214	05/12/2025 13:56:32	1345897338271298	XLON
147	1212	05/12/2025 13:59:26	1345897338271706	XLON
7	1212	05/12/2025 14:25:29	1345897338273806	XLON

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

Camarco (Financial PR) [email protected]

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSUPGPPPUPAPWM

AI Terminal

7590_pos_2025-12-08_729d7c60-570c-49fd-bd36-64ea9bab78fa.html

More from CVS GROUP PLC

Talk to a Data Expert